Loading data for PLYX — first visit, this takes a few seconds.
Polaryx Therapeutics Inc. (PLYX)
NasdaqCM: PLYX
· Real-Time Price · USD
2.09
-0.01 (-0.48%)
At close: Aug 18, 2026, 8:00 PM
Polaryx Therapeutics Inc. (PLYX) Stock Price, Analysis & Data
-0.48% (1D)
No data available
| Bid | 1.53 |
| Market Cap | 104.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.85M |
| Beta | n/a |
| EPS (ttm) | -0.14 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 39.43 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2.63 |
| Volume | 82,774 |
| Avg. Volume (20D) | 179,367 |
| Open | 2.13 |
| Previous Close | 2.10 |
| Day's Range | 2.07 - 2.16 |
| 52-Week Range | 1.86 - 48.91 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PLYX
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combi...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 2, 2026
Employees 2
Stock Exchange NasdaqCM
Ticker Symbol PLYX
Website https://polaryx.com
Financial Performance
In 2025, Polaryx Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -8.98M, a decrease of -70.4%.
Financial StatementsEarnings Surprise
Polaryx Therapeutics has released their quarterly earnings on Aug 13, 2026:
